| TP | TS | TFS | |
| Cost (2006 CAN$) | 2678 (1950 to 3536) | 2801 (2306 to 3362) | 4042 (3228 to 4994) |
| Exacerbations per year | 1.56 (1.34 to 1.81) | 1.69 (1.47 to 1.94) | 1.35 (1.16 to 1.55) |
| QALY | 0.7092 (0.6953 to 0.7228) | 0.7124 (0.6931 to 0.7310) | 0.7217 (0.7034 to 0.7389) |
| Adjusted incremental QALY* | 0 (reference) | −0.0052 (−0.0088 to 0.0032) | 0.0056 (−0.0142 to 0.0251) |
| Incremental cost per exacerbation avoided | Reference | Dominated | 6510 |
| Incremental cost per QALY | Reference | Dominated | 243180 |
*Incremental QALYs are adjusted for the baseline utility using a linear regression model.
CAN$, Canadian dollars; TFS, tiotropium+fluticasone/salmeterol; TP, tiotropium+placebo; TS, tiotropium+salmeterol; QALY, quality adjusted life years.